pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO
Agios Netherlands
Agios Netherlands B.V.
Agios Netherlands is a pharma organization headquartered in CAMBRIDGE, MA, NL. It trades on NYSE under ticker AGIO. Primary therapeutic focus areas include Pyruvate Kinase Deficiency, Sickle Cell Disease, Transfusion-dep
CAMBRIDGE, MA, NL HQ
1978 Founded
20 Employees
Public company Type
AGIO · NYSE Ticker
Company details
- Status
- Public
- HQ
- CAMBRIDGE, MA, NL
- Founded
- 1978
- Employees
- 20
- Programs
- 45
- Drugs
- 15
- Patents
- 93
ivosidenib and nivolumab
Phase 2 · small molecule · Advanced Solid Tumor
ivosidenib and nivolumab for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Agios Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code HCC 19-096
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Agios Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced Solid Tumor
- Status
- completed
- Trials
- 1